Target intelligence / Profile preview

Beta Amyloid Peptide Aggregate

Molecular classification
Protein aggregate, Peptide aggregate
01

Overview

Beta amyloid peptide aggregates are assemblies of amyloid beta (Aβ) peptides, which are short sequences of 36–43 amino acids derived from the proteolytic cleavage of the amyloid precursor protein (APP). These aggregates are a hallmark feature in the brains of individuals with Alzheimer's disease and play a central role in its pathogenesis. Aggregated Aβ is neurotoxic and disrupts cellular function through several mechanisms, including inducing synaptic dysfunction, triggering inflammatory responses, promoting cell-to-cell transmission within brain tissue and impairing clearance mechanisms leading to further accumulation.

Other names
Aβ aggregatesAmyloid plaquesAmyloid beta oligomersAmyloid beta fibrilsAβ oligomersAβ fibrils
02

Mechanism of action

Inhibition of aggregation, promotion of disaggregation, neutralization of toxic aggregates, modulation of APP processing

03

Biological functions

Synaptic dysfunction inductionInflammatory response triggeringCell-to-cell transmission within brain tissueImpairment of clearance mechanisms
04

Disease associations

Alzheimer's diseaseNeurodegenerative disease
05

Safety considerations

Potential for off-target effects of aggregation inhibitorsDifficulty in achieving sufficient brain penetrationRisk of triggering inflammatory responsesComplex interplay between different Aβ species
06

Interacting drugs

Small molecules inhibiting aggregation

4 more in the full profile.

07

Biomarkers

Aβ40 levelsAβ42 levelsAmyloid PET imaging

Beyond the preview

Go deeper on Beta Amyloid Peptide Aggregate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta Amyloid Peptide Aggregate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call